Inducing CD8<sup>+</sup> Tregs Limits Atherosclerosis via Notch-Mediated VSMC Quiescence.

Gao, Wentao; Hou, Yangfeng; Liu, Jiaxing; Ho, Cheng Kiu; Cheng, Alfred Sze-Lok; Waldmann, Herman; Zhou, Bin; Lau, James Y W et al. · Circ Res · 2026

basic_science · Level V

Where this comes from

Abstract

CD8<sup>+</sup> (cluster of differentiation 8) T cells contribute to atherosclerosis, but how they affect VSMCs (vascular smooth muscle cells) is unclear. The protective role of CD8<sup>+</sup> regulatory T cells (Tregs) and in vivo induction strategies also remain undefined. We analyzed human atherosclerosis single-cell RNA sequencing to map immune-VSMC communication. Atherosclerosis was modeled in adeno-associated virus-<i>Pcsk9</i> or <i>Apoe</i><sup><i>-/-</i></sup> mice. CD8<sup>+</sup> T-cell activity was modulated by adoptive transfer of CD45.1<sup>+</sup>CD8<sup>+</sup> T cells into syngeneic CD45.2<sup>+</sup> <i>Apoe</i><sup><i>-/-</i></sup> recipients (gain-of-function) or nonlytic anti-CD8α antibodies (loss-of-function). VSMC-specific Notch loss was tested in <i>Myh11</i><sup><i>CreER</i></sup><i>;Rbpj</i><sup><i>fl/fl</i></sup><i>;Apoe</i><sup><i>-/-</i></sup> mice. Ligand-receptor interactions were perturbed with neutralizing antibodies. Lineage tracing was performed using <i>Myh11</i><sup><i>CreER</i></sup><i>;Rosa</i><sup><i>YFP</i></sup><i>;Apoe</i><sup><i>-/-</i></sup> mice. CD8<sup>+</sup>CD44<sup>+</sup>CD122<sup>+</sup> Tregs were adoptively transferred to assess therapeutic potential. Transcription factor chromatin immunoprecipitation sequencing (ChIP-seq) was used to define VSMC gene regulation. CD8<sup>+</sup> T cells are the dominant immune partners communicating with VSMCs via CD8α in human plaques. Transferred CD8<sup>+</sup> T cells localize to the media and inhibit VSMC Notch signaling. VSMC Notch ablation accelerates atherosclerosis, enhancing VSMC proliferation, inflammation, and phenotypic switching. CD8α blockade induces CD8<sup>+</sup>CD44<sup>+</sup>CD122<sup>+</sup> Tregs, which, partly via IL-10 (interleukin-10), activate VSMC Notch, suppress proliferation, and limit VSMC-to-macrophage transdifferentiation. These Tregs express higher Notch ligands than conventional CD8<sup>+</sup> T cells and decline with a high-cholesterol diet. Their adoptive transfer slows atherosclerosis progression. Blocking Notch1-Jag2 (Jagged 2), or synergistically blocking DLL1/4 (delta-like ligand 1/4) and Jag1/2, negates Treg protection. Mechanistically, Notch-RBPJ (recombination signal binding protein for immunoglobulin kappa J region) activates <i>Hes1</i>, which suppresses <i>Klf4</i> and <i>Rel</i> via Hes1/EZH2-mediated trimethylation of histone H3 at lysine 27. CD8<sup>+</sup> T cells promote atherosclerosis by inhibiting VSMC Notch; CD8<sup>+</sup>CD44<sup>+</sup>CD122<sup>+</sup> Tregs restore Notch, preserve VSMC quiescence, and stabilize plaques. The CD8<sup>+</sup> Treg-Notch axis is a novel and promising therapeutic target against atherosclerosis.